Partners Howard Young and Stephen Forster spoke with The Legal Intelligencer about the potential for an uptick in life sciences transactions under the incoming Trump-Vance Administration. Both Howard and Stephen noted that policy decisions by the new administration are likely to influence the pace of deals in the sector.
“There’s been a lot of capital on the sidelines that is ready to be deployed and particularly if there’s a little more certainty in terms of antitrust review … [and] on how the federal agencies will view the potential mergers and affiliations and the like,” Howard said. “Broadly speaking and assuming the cost of capital doesn’t go up … generally speaking we expect more robust dealflow.”
“If the Trump administration is conservative or pulls back slightly on the Inflation Reduction Act, we could see potentially that the money on the sidelines may come back into play, including additional deals in assets, acquisitions, molecules, or pipeline aspects,” Stephen said.